- Home
- UEIC vs EDIT Comparison
UEIC vs EDIT Comparison
Compare UEIC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UEIC
- EDIT
- Stock Information
- Founded
- UEIC 1986
- EDIT 2013
- Country
- UEIC United States
- EDIT United States
- Employees
- UEIC N/A
- EDIT N/A
- Industry
- UEIC Consumer Electronics/Appliances
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UEIC Consumer Staples
- EDIT Health Care
- Exchange
- UEIC Nasdaq
- EDIT Nasdaq
- Market Cap
- UEIC 79.4M
- EDIT 108.1M
- IPO Year
- UEIC 1993
- EDIT 2016
- Fundamental
- Price
- UEIC $6.16
- EDIT $1.25
- Analyst Decision
- UEIC Strong Buy
- EDIT Buy
- Analyst Count
- UEIC 2
- EDIT 14
- Target Price
- UEIC $14.50
- EDIT $8.08
- AVG Volume (30 Days)
- UEIC 89.7K
- EDIT 2.5M
- Earning Date
- UEIC 05-01-2025
- EDIT 03-05-2025
- Dividend Yield
- UEIC N/A
- EDIT N/A
- EPS Growth
- UEIC N/A
- EDIT N/A
- EPS
- UEIC N/A
- EDIT N/A
- Revenue
- UEIC $394,879,000.00
- EDIT $32,314,000.00
- Revenue This Year
- UEIC $3.65
- EDIT N/A
- Revenue Next Year
- UEIC $9.05
- EDIT N/A
- P/E Ratio
- UEIC N/A
- EDIT N/A
- Revenue Growth
- UEIC N/A
- EDIT N/A
- 52 Week Low
- UEIC $6.10
- EDIT $1.12
- 52 Week High
- UEIC $14.20
- EDIT $7.41
- Technical
- Relative Strength Index (RSI)
- UEIC 26.50
- EDIT 41.70
- Support Level
- UEIC $6.44
- EDIT $1.24
- Resistance Level
- UEIC $6.96
- EDIT $1.32
- Average True Range (ATR)
- UEIC 0.34
- EDIT 0.11
- MACD
- UEIC 0.05
- EDIT -0.03
- Stochastic Oscillator
- UEIC 5.17
- EDIT 2.94
About UEIC Universal Electronics Inc.
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.